Rasha Aguzzi

Also affiliated with AstraZeneca (United States)

MedicineImmunology and Microbiology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 1 paper. Top paper: “Long-term Efficacy and Safety of Ravulizumab, a Long-acting Terminal Complement Inhibitor, in Adults With Anti-acetylcholine Receptor Antibody-positive Generalized Myasthenia Gravis: Final Results From the Phase 3 CHAMPION MG Open-label Extension”.

Long-term Efficacy and Safety of Ravulizumab, a Long-acting Terminal Complement Inhibitor, in Adults With Anti-acetylcholine Receptor Antibody-positive Generalized Myasthenia Gravis: Final Results From the Phase 3 CHAMPION MG Open-label Extension

Neurology(2024)10.1212/01.wnl.0001051364.68802.aa

N/A

0DataRank · unranked

0 citations

Renato Mantegazza, Djillali Annane, Masahisa Katsuno, Andreas Meisel, Michael Nicolle +5 more